AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025

Preclinical data highlights potential in treating Alzheimer’s disease

AlzeCure Pharma AB announced that its abstract on NeuroRestore ACD856 has been accepted for presentation at the AD/PD 2025 conference.

The abstract will be presented by Gunnar Nordvall, Head of Chemistry at AlzeCure, in Vienna from April 1-5.

The abstract, titled ‘Further investigation on the immunomodulatory and anti-inflammatory effects of NeuroRestore ACD856’, will highlight the drug’s potential in treating Alzheimer’s disease. The data shows ACD856 affects biomarkers relevant to pathological neuroinflammatory processes.

“Our results show that ACD856 could have an effect on both central and peripheral inflammatory processes,” said Nordvall. “These new data are promising and further broaden the disease-modifying potential of ACD856, as neuroinflammation is an important part of the disease process in Alzheimer’s.”

Previous studies have indicated that NeuroRestore compounds improve cognitive abilities, including learning and memory functions. They also show neuroprotective and anti-inflammatory effects, with increased BDNF and NGF signalling.

“These positive results add to the case that NeuroRestore ACD856 could be relevant for additional indications with an inflammatory component, such as other neurodegenerative diseases,” said Martin Jönsson, CEO of AlzeCure Pharma AB. “This further strengthens our commercial opportunities with ACD856.”

ACD856, AlzeCure’s lead drug candidate within the NeuroRestore platform, is being prepared for phase 2 clinical studies. The unique pharmacological mechanism of NeuroRestore enables multiple indications, including Alzheimer’s, Parkinson’s disease, and depression.

The abstract includes contributions from Christina Parrado-Fernández, Veronica Lidell, Azita Rasti, Maria Backlund, Johan Sandin and Pontus Forsell from AlzeCure, and Ruchi Gera, Sumonto Mitra and Professor Maria Eriksdotter from Karolinska Institutet.

The international conference on Alzheimer’s, Parkinson’s and Related Neurological Diseases will provide a platform for presenting these promising preclinical study results.